Latest Ratios: P/E Ratio -13.1x · EV/EBITDA N/A · ROE -132.5%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $50M | $75M | $51M | $15M | $74M | $90M | — | — |
| Enterprise Value | $-80408689 | $-55679840 | $4M | $-17077200 | $-26745380 | $-87615976 | — | — |
| P/E Ratio → | -13.07 | — | — | — | — | — | — | — |
| P/S Ratio | 0.91 | 1.71 | 8.05 | — | — | — | — | — |
| P/B Ratio | 1.81 | 2.12 | 2.90 | 0.41 | 0.70 | 0.48 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -1.27 | 0.62 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.5% | 96.5% | 100.0% | — | — | — | — | — |
| Operating Margin | -95.9% | -95.9% | -954.9% | — | — | — | — | — |
| Net Profit Margin | -80.1% | -80.1% | -918.0% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -132.5% | -132.5% | -214.0% | -107.3% | -60.6% | -84.2% | -332.4% | -45.0% |
| ROA | -31.0% | -31.0% | -88.2% | -76.4% | -48.9% | -58.8% | -111.5% | -27.6% |
| ROIC | — | — | — | -1207.8% | -1004.5% | -2056.0% | -1446.3% | — |
| ROCE | -59.0% | -59.0% | -136.5% | -97.1% | -54.5% | -67.3% | -152.2% | -33.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.46 | 0.34 | 0.19 | 0.11 | — | 0.48 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -3.70 | -2.68 | -0.87 | -0.95 | -0.96 | — | -0.78 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -596.45 | — | — | -125.33 | -91.03 | — |
Net cash position: cash ($138M) exceeds total debt ($7M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.58 | 2.58 | 2.21 | 3.02 | 5.89 | 15.85 | 0.93 | 9.81 |
| Quick Ratio | 2.58 | 2.58 | 2.21 | 3.02 | 5.89 | 15.85 | 0.93 | 9.81 |
| Cash Ratio | 2.44 | 2.44 | 2.03 | 2.80 | 5.70 | 15.50 | 0.87 | 9.38 |
| Asset Turnover | — | 0.28 | 0.09 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 41.70 | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $8M | $4M | $2M | $2M | $400451 | $37413 | $29236 |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XLO stock.
Xilio Therapeutics, Inc.'s current P/E ratio is -13.1x. This places it at the 50th percentile of its historical range.
Xilio Therapeutics, Inc.'s return on equity (ROE) is -132.5%. The historical average is -139.4%.
Based on historical data, Xilio Therapeutics, Inc. is trading at a P/E of -13.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Xilio Therapeutics, Inc. has 96.5% gross margin and -95.9% operating margin.
Key Metrics
Top Statement Risk
Cash burn against lumpy collaboration revenue
Metrics are mathematically derived from official filings.
Negative Earnings Leave Sales Multiple Anchoring Valuation
Based on the reported trailing figures, XLO trades at a P/E of -2.06 and a P/S of 3.82 with a P/B of 20.43, leaving the sales multiple as the only meaningful earnings-independent anchor for a company without positive profits.
With trailing net income negative, the P/E ratio carries no interpretive weight and the sales multiple becomes the primary reference point, though a 3.82 P/S is hard to justify against revenue that swung from $2.9M to $19.1M across the period. The P/B of 20.43 compared with a retained deficit of -$434.7M suggests the market is pricing pipeline value rather than book equity, and investors should monitor whether the valuation depends on milestone recognition that may not repeat. Peer multiples are not comparable on earnings for most of the group, since NKTX, IMVT, and CLDX also carry negative P/E, so the comparison rests on P/B and pipeline assumptions that the supplied data cannot verify.
Minimal Debt Keeps Leverage Largely Irrelevant
As reported in the balance sheet, XLO's D/E ratio sits near 0.09 in 2026Q2 with total debt of $6.3M, while interest coverage and EBITDA-based leverage are unavailable because operating earnings are negative.
The debt load has drifted down from $8.9M over ten quarters, and at this scale it does not constrain the company's financing position on its own. Interest coverage and Debt/EBITDA cannot be meaningfully computed given negative operating income, so the data does not allow a judgment on debt service comfort. The more relevant risk is equity-funded dilution and milestone-dependent financing rather than covenant or refinancing pressure, which warrants monitoring given the scale of ongoing operating losses.
Cash Buffer Covers Liabilities Substantially
Based on reported figures, XLO's current ratio of 4.25 in 2026Q2 and cash of $136.0M against $82.0M of total liabilities suggest a substantial near-term buffer, though deferred revenue of $35.3M may tie up part of that cash.
A current ratio that climbed from 1.67 to 4.25 over the period suggests the balance sheet has been rebuilt through capital and collaboration inflows, not through operating profit. Because quick and current ratios are identical here and inventory is absent for a research-stage model, the ratio is a clean read on cash versus obligations. Investors should note that deferred revenue obligations may reduce the economic freedom of the cash balance, and a stress case that assumes continued quarterly burn would deplete this buffer faster than the headline ratio implies.
Returns Oscillate Without Compounding Pattern
As reported in quarterly data, XLO's ROE moved from -94% to 76% and back to -18% across recent quarters, with ROIC reported only once at -6.1%, so the return trend reflects one-off items rather than durable capital efficiency.
The swing in ROE is driven by net income volatility from collaboration revenue and non-operating items, not by an improving operating base, since operating margin remained negative in most quarters. With ROIC data sparse, a multi-year compounding view cannot be established, and investors should treat the positive ROE quarter as a timing artifact rather than evidence of sustained returns. Relative to TGTX, which reports ROIC of 16.4%, XLO's economics remain far from proven at the operating level.
Quick Ratio Obscures Cash Burn Dependence
The current ratio is most commonly used as a comfort metric for biotech balance sheets, but for XLO it hides that 4.25 coverage reflects episodic inflows against persistent free cash outflow.
A healthy current ratio says nothing about the rate at which cash is consumed, and a company with negative free cash flow in most quarters may see that coverage erode quickly. The more useful measure is cash runway, calculated as cash divided by average quarterly operating burn, which the supplied data supports directionally but does not state explicitly. Investors should monitor how much of the $136.0M cash position is restricted by deferred revenue obligations before treating the liquidity ratio as a measure of financial strength.